Esperion Therapeutics (ESPR) Expected to Release Earnings on Tuesday

Esperion Therapeutics (NASDAQ:ESPR) is projected to post its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Esperion Therapeutics to announce earnings of ($0.02) per share and revenue of $92.4770 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:00 AM ET.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Friday, May 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.08). Esperion Therapeutics had a net margin of 0.12% and a negative return on equity of 0.14%. The company had revenue of $80.10 million for the quarter, compared to the consensus estimate of $84.52 million.

Esperion Therapeutics Price Performance

ESPR stock remained flat at $3.18 during midday trading on Tuesday. The stock has a fifty day moving average price of $3.16 and a 200 day moving average price of $2.99. The stock has a market capitalization of $819.45 million, a P/E ratio of -53.00 and a beta of 1.07. Esperion Therapeutics has a one year low of $1.10 and a one year high of $4.18.

Insider Buying and Selling

In related news, CFO Benjamin Halladay sold 10,773 shares of the stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $3.15, for a total transaction of $33,934.95. Following the transaction, the chief financial officer owned 702,829 shares of the company’s stock, valued at approximately $2,213,911.35. This trade represents a 1.51% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Benjamin Looker sold 11,824 shares of Esperion Therapeutics stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $3.15, for a total transaction of $37,245.60. Following the completion of the transaction, the insider owned 667,524 shares in the company, valued at approximately $2,102,700.60. The trade was a 1.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 1.60% of the company’s stock.

Institutional Trading of Esperion Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Sivia Capital Partners LLC bought a new position in shares of Esperion Therapeutics during the second quarter valued at about $25,000. Kestra Advisory Services LLC bought a new stake in shares of Esperion Therapeutics in the 4th quarter valued at about $35,000. Captrust Financial Advisors bought a new stake in shares of Esperion Therapeutics in the 4th quarter valued at about $40,000. CIBC Bancorp USA Inc. purchased a new stake in Esperion Therapeutics during the 3rd quarter valued at about $56,000. Finally, Cibc World Markets Corp bought a new position in Esperion Therapeutics during the 4th quarter worth approximately $57,000. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Jefferies Financial Group downgraded shares of Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 1st. Citizens Jmp downgraded Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 1st. Cantor Fitzgerald lowered Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 1st. Piper Sandler lowered Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 1st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Esperion Therapeutics presently has an average rating of “Hold” and a consensus price target of $5.54.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.